GEN Exclusives

More »

GEN News Highlights

More »
Jul 28, 2009

U.K. DMD Charity to Provide AVI BioPharma $1.2M to Progress Drugs

  • Action Duchenne has earmarked about $1.2 million for a collaboration focused on progressing AVI BioPharma’s exon-skipping drug candidates for the treatment of duchenne muscular dystrophy (DMD).

    The company reports that its lead candidate, AVI-4658, is designed to skip exon 51 of the dystrophin gene, restoring the reading frame of the mRNA sequence, and resulting in a truncated but potentially functional form of the dystrophin protein. A dose-finding clinical trial evaluating systemic delivery of AVI-4658 is currently under way in the U.K.

    A second, preclinical-stage candidate, AVI-5038, is based on a second generation of AVI BioPharma’s phosphorodiamidate morpholino oligomer antisense chemistry and is deisgned to skip Exon 50.

     



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Using CRISPRs to Tame GMOs

With more climate-induced droughts and insect infestations on the horizon do you think technologies like CRISPR will change a lot of people’s minds about GMOs, including genetically engineered foods?

More »